about
Antiangiogenic mechanisms and factors in breast cancer treatmentTherapeutic Use of Native and Recombinant EnterovirusesCancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple IntegrinsRadiolabeled cyclic RGD peptides as radiotracers for tumor imagingRGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cellsPlasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment.Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopyFITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues.Integrin targeted delivery of radiotherapeutics.Integrin targeted delivery of chemotherapeuticsMolecular imaging in tumor angiogenesis and relevant drug researchProstate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.Near-Infrared Confocal Laser Endomicroscopy Detects Colorectal Cancer via an Integrin αvβ 3 Optical Probe.Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.Exploration of peptide T7 and its derivative as integrin αvβ3-targeted imaging agents.Optimization of RGD-Containing Cyclic Peptides against αvβ3 IntegrinExperimental Adaptation of Rotaviruses to Tumor Cell Lines.Development of individualized anti-metastasis strategies by engineering nanomedicinesSystemic Administration of siRNA via cRGD-containing Peptide.Stroma targeting nuclear imaging and radiopharmaceuticals.Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma models.(64)Cu-NODAGA-c(RGDyK) Is a Promising New Angiogenesis PET Tracer: Correlation between Tumor Uptake and Integrin α(V)β(3) Expression in Human Neuroendocrine Tumor XenograftsThe Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice.Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers.Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA constructIntegrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects.Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.Integrin targeted drug and gene delivery.Therapeutic modulation of prostate cancer metastasis.Redefining the role(s) of endothelial αvβ3-integrin in angiogenesis.Actin-tethered junctional complexes in angiogenesis and lymphangiogenesis in association with vascular endothelial growth factor.Platelet-targeted pharmacologic treatments as anti-cancer therapy.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Low levels of physiological interstitial flow eliminate morphogen gradients and guide angiogenesis.Arg-Gly-Asp-D-Phe-Lys peptide-modified PEGylated dendrimer-entrapped gold nanoparticles for targeted computed tomography imaging of breast carcinoma.Selective Cell Adhesion and Biosensing Applications of Bio-Active Block Copolymers Prepared by CuAAC/Thiol-ene Double Click Reactions.Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma.Efficient bioconjugation of 5-fluoro-5-deoxy-ribose (FDR) to RGD peptides for positron emission tomography (PET) imaging of α(v)β(3) integrin receptor.
P2860
Q26751226-5E8907ED-C784-47A8-ACF3-30EBB4DF7ADBQ26767082-140D8A73-77C3-43F8-BFE7-7F8B57480290Q26778150-2B12DC9D-4825-43C5-BC82-014F80BDB409Q26801806-5648A23D-B85B-466C-9AA4-3E91B5B92DBEQ28072021-9C349A45-29B7-45E0-825B-0BFE3E149AD3Q28543148-6FB76830-6893-48D2-B627-E50DF26FC636Q33910532-1C387BA0-19E9-4539-8EB4-328E7B11DD0DQ34050862-F8374F7C-180F-40A7-BF7F-450194AB5479Q34556242-0AF9A8C6-EED4-4F96-A3C4-20FB69857071Q34912696-B3C67CE1-EE54-41D0-AD18-7B91789CD49FQ34912725-B646BEBA-7A4F-47F7-89B1-FBB20E90D397Q35130907-91206621-D871-404C-B047-92FA9D26A4FDQ35195521-E566B879-D655-4D4D-8EBC-A59EB831A636Q35549455-BFC95715-72E2-4518-B46A-CE57B3FFF576Q35674830-9E479CCA-0B19-4E93-AF2F-C01ADAE127FFQ35760732-62F5960F-CE81-4A05-BF6D-996C5AEB4FE5Q35882341-C8E58703-54F5-480C-935B-D989700EA2DCQ35909654-6F4E0DAA-CE76-4C13-8D0E-DD6B3BDDBBFAQ35967474-84FFB159-81EF-46A5-B73F-736731EA29A7Q35989535-D9FACEAE-FC7F-424C-A077-35FCCD6D67DDQ35999606-EF5E2A07-5138-4C30-B24F-C6401AD237A6Q36111439-6113235A-ADA1-4C77-8FDB-967401383C6DQ36311285-C6A2F8E1-A3AC-4722-871A-179F1F2262B7Q36507002-8FF9229C-089B-4211-BEF6-6CA603E74DECQ36777406-E1905EB5-7C1A-4E28-BFF6-200EACC4784AQ37059663-3FADFAB4-2C68-4DCB-9A42-6CC0796D5F8DQ37410430-FA06913F-4A0D-492F-9364-DB52E167122CQ37558860-D974E2D5-6389-47BB-8BE9-4206A49F668CQ37592073-D67FDD74-978E-4239-9985-36D5B1B94008Q37679945-24EC83FC-F811-4E4A-B2F0-04B99D51E6A5Q38182140-0D2EA852-03F8-4CE8-AB2B-2D0FC74DCD04Q38268451-18F0CA32-3B19-4CF4-B949-65A188406CF6Q38425671-DBF7D25F-FD4B-4C6E-AB76-6BD6DF4470C5Q38657846-EF8D387D-7E3C-4EBA-9FF4-931F37699D10Q38676164-C2C41C4F-7F4B-494B-9A1F-BF328F1290A1Q38728427-4CB09330-E87D-4F1F-95D7-F9F5E14F0937Q38848923-6BBA27D3-85AC-4A9E-AB6D-C1E70C92D4FDQ38874898-FE8637E7-A0F6-44C5-9319-E683F2D0D56AQ39102336-97150904-4DEE-45B2-8150-FDC47470B349Q39144300-6D3D6D71-A600-43C4-AC80-2BC45558ACFA
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
@ast
Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
@en
type
label
Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
@ast
Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
@en
prefLabel
Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
@ast
Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
@en
P2860
P356
P1476
Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
@en
P2093
P2860
P304
P356
10.1002/DDR.20265
P577
2008-01-01T00:00:00Z